Story perspectives

Pfizer Q4 Earnings Surge 22% Despite Covid Sales Drop

2/4/2025

47 9

Summary

Story summary

Pfizer Inc. reported Q4 2024 earnings of $17.76 billion, marking a 22% year-over-year increase and adjusted EPS of $0.63.
The company projects 2025 revenues of $61-64 billion and adjusted EPS of $2.80-3.00, despite declining Covid product sales.
Paxlovid sales reached $727 million, while Comirnaty sales dropped to $3.4 billion due to lower vaccination rates.
Pfizer aims for $4.5 billion in cost savings by 2025 to improve operational efficiency amid market challenges.

History

Historical Context

Pfizer's Q4 2024 earnings reflect a significant post-pandemic recovery, reminiscent of the pharmaceutical industry's rebound after the 2008 financial crisis. Both periods saw companies adapt to market shifts, emphasizing operational efficiency amid declining product demand. Historical resilience shapes today's strategies for navigating economic challenges.

1 of 2

Story summary

Pfizer Inc. reported Q4 2024 earnings of $17.76 billion, marking a 22% year-over-year increase and adjusted EPS of $0.63.
The company projects 2025 revenues of $61-64 billion and adjusted EPS of $2.80-3.00, despite declining Covid product sales.
Paxlovid sales reached $727 million, while Comirnaty sales dropped to $3.4 billion due to lower vaccination rates.
Pfizer aims for $4.5 billion in cost savings by 2025 to improve operational efficiency amid market challenges.

1 / 2